PLoS ONE (Jan 2024)

Elimination of 15N-thymidine after oral administration in human infants.

  • Niyatie Ammanamanchi,
  • Jessie Yester,
  • Anita P Bargaje,
  • Dawn Thomas,
  • Kathryn C Little,
  • Shannon Janzef,
  • Kimberly Francis,
  • Jacqueline Weinberg,
  • Jennifer Johnson,
  • Thomas Seery,
  • Tyler Hutchinson Harris,
  • Bryan J Funari,
  • Kirsten Rose-Felker,
  • Matthew Zinn,
  • Susan A Miller,
  • Shawn C West,
  • Brian Feingold,
  • Hairu Zhou,
  • Matthew L Steinhauser,
  • Timothy Csernica,
  • Robert Michener,
  • Bernhard Kühn

DOI
https://doi.org/10.1371/journal.pone.0295651
Journal volume & issue
Vol. 19, no. 1
p. e0295651

Abstract

Read online

BackgroundWe have developed a new clinical research approach for the quantification of cellular proliferation in human infants to address unanswered questions about tissue renewal and regeneration. The approach consists of oral 15N-thymidine administration to label cells in S-phase, followed by Multi-isotope Imaging Mass Spectrometry for detection of the incorporated label in cell nuclei. To establish the approach, we performed an observational study to examine uptake and elimination of 15N-thymidine. We compared at-home label administration with in-hospital administration in infants with tetralogy of Fallot, a form of congenital heart disease, and infants with heart failure.MethodsWe examined urine samples from 18 infants who received 15N-thymidine (50 mg/kg body weight) by mouth for five consecutive days. We used Isotope Ratio Mass Spectrometry to determine enrichment of 15N relative to 14N (%) in urine.Results/findings15N-thymidine dose administration produced periodic rises of 15N enrichment in urine. Infants with tetralogy of Fallot had a 3.2-fold increase and infants with heart failure had a 4.3-fold increase in mean peak 15N enrichment over baseline. The mean 15N enrichment was not statistically different between the two patient populations (p = 0.103). The time to peak 15N enrichment in tetralogy of Fallot infants was 6.3 ± 1 hr and in infants with heart failure 7.5 ± 2 hr (mean ± SEM). The duration of significant 15N enrichment after a dose was 18.5 ± 1.7 hr in tetralogy of Fallot and in heart failure 18.2 ± 1.8 hr (mean ± SEM). The time to peak enrichment and duration of enrichment were also not statistically different (p = 0.617 and p = 0.887).ConclusionsThe presented results support two conclusions of significance for future applications: (1) Demonstration that 15N-thymidine label administration at home is equivalent to in-hospital administration. (2) Two different types of heart disease show no differences in 15N-thymidine absorption and elimination. This enables the comparative analysis of cellular proliferation between different types of heart disease.